Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Emerging drugs for premature ejaculation.

Marcel D Waldinger¹

¹Department of Psychiatry and Neurosexology, HagaHospital Leyenburg, Leyweg 275, 2545 CH, The Hague, The Netherlands. md@waldinger.demon.nl

Expert Opinion on Emerging Drugs

|March 1, 2006

Summary

Lifelong premature ejaculation (PE) is a common male sexual dysfunction. Combining SSRIs with 5-HT(1A) receptor antagonists may offer new on-demand treatments for PE.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Men with subjective premature ejaculation have a similar lognormal IELT distribution as men in the general male population and differ mathematically from males with lifelong premature ejaculation after an IELT of 1.5 minutes (Part 2).

International journal of impotence research·2019

Same author

Use of a confirmed mathematical method for back-analysis of IELT distributions: ejaculation time differences between two continents and between continents and men with lifelong premature ejaculation (Part 1).

International journal of impotence research·2019

Same author

Differences between ICD-11 MMS and DSM-5 definition of premature ejaculation: a continuation of historical inadequacies and a source of serious misinterpretation by some European Regulatory Agencies (PART 2).

International journal of impotence research·2019

Same author

Method and design of drug treatment research of subjective premature ejaculation in men differs from that of lifelong premature ejaculation in males: proposal for a new objective measure (part 1).

International journal of impotence research·2019

Same author

Drug treatment options for premature ejaculation.

Expert opinion on pharmacotherapy·2018

Same author

Tramadol's Inhibitory Effects on Sexual Behavior: Pharmacological Studies in Serotonin Transporter Knockout Rats.

Frontiers in pharmacology·2018

Area of Science:

Neuroscience
Urology
Pharmacology

Background:

Premature ejaculation (PE) is a frequent male sexual dysfunction.
Lifelong PE is characterized by rapid ejaculation, often within 2 minutes, starting in adolescence.
PE can lead to psychological, sexual, and relationship issues.

Purpose of the Study:

Investigate the neurobiological underpinnings of lifelong PE.
Evaluate current and potential new pharmacological treatments for PE.
Explore novel on-demand therapeutic strategies for PE.

Main Methods:

Review of existing literature on PE neurobiology and treatments.
Analysis of serotonergic (5-hydroxytryptamine; 5-HT) neurotransmission pathways.
Examination of animal studies on SSRI and 5-HT receptor antagonist combinations.

Main Results:

Lifelong PE is linked to serotonergic neurotransmission disturbances.
Daily SSRIs delay ejaculation but cause side effects.
On-demand SSRIs show less efficacy than daily use.
Animal studies suggest SSRI and 5-HT(1A) antagonist combinations induce rapid ejaculation delay.

Conclusions:

Novel on-demand treatments for PE may involve combining SSRIs with compounds that rapidly enhance 5-HT neurotransmission.
Targeting 5-HT(1A) receptors alongside SSRIs shows promise for effective PE management.
Further research into combination therapies could lead to improved PE treatments.

Related Experiment Videos